Livio Trusolino

Cited by

	All	Since 2016
Citations	13422	7404
h-index	55	39
i10-index	90	75

1900

950

475

1425

19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202145 58 71 70 136 170 199 224 224 234 256 285 390 428 570 664 862 972 1153 1388 1315 1567 1888 70

Co-authors

Andrea BertottiUniversity of Torino - School of MedicineVerified email at ircc.it
Alberto BardelliUniversity of Torino - Candiolo Cancer Institute IRCCSVerified email at ircc.it
francesco sassiIRCC-University of Torino School of Medicine, Laboratory of Molecular Pharmacology ItalyVerified email at ircc.it
Enzo MedicoProfessor of Histology, University of Torino and Head of the Laboratory of Oncogenomics, CandioloVerified email at ircc.it
Claudio IsellaIRCCVerified email at ircc.it
Salvatore SienaUniversità degli Studi di Milano, Niguarda Cancer Center, Grande Ospedale Metropolitano NiguardaVerified email at unimi.it
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyVerified email at ospedaleniguarda.it
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoliVerified email at unina2.it
Simona CorsoUniversity of TorinoVerified email at ircc.it
Luca LazzariIFOM - FIRC Institute of Molecular OncologyVerified email at ifom.eu
Jos JonkersGroup Leader and Head of Division of Molecular Pathology, Netherlands Cancer Institute, OncodeVerified email at nki.nl
Alessandro AMOREOspedale Regina Margherita Torino, Università degli studi TorinoVerified email at unito.it
Lorenzo CapussottiChief of the Surgical Deparment- Ospedale Mauriziano "Umberto I" TorinoVerified email at mauriziano.it
Guido SeriniGroup Leader, Candiolo Cancer Institute & Professor, University of Torino, ItalyVerified email at ircc.it
Dario RiberoDirigente Medico I livello, Divisione di Chirurgia Generale ed Oncologica, Ospedale Mauriziano Umberto IVerified email at mauriziano.it
Charlotte RolnyAssociate professor of tumor biology, Karolinska Institute, SwedenVerified email at ki.se
Lodewyk WesselsProfessor of Computational Cancer BiologyVerified email at nki.nl
Giuseppe Bassoprofessor of pediatrics university paduaVerified email at unipd.it
Massimiliano MazzoneGroup Leader, Vesalius Research CenterVerified email at vib-kuleuven.be
Andrea CasazzaSenior Scientist @ CoBioRes NV, BelgiumVerified email at cobiores.be

Livio Trusolino

Professor, University of Torino School of Medicine, Italy

Verified email at ircc.it - Homepage

Targeted anti-cancer therapies animal models oncogenic signal transduction pathways


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
MET signalling: principles and functions in development, organ regeneration and cancer L Trusolino, A Bertotti, PM Comoglio Nature reviews Molecular cell biology 11 (12), 834-848, 2010	1030	2010
Patient-derived xenograft models: an emerging platform for translational cancer research M Hidalgo, F Amant, AV Biankin, E Budinská, AT Byrne, C Caldas, ... Cancer discovery 4 (9), 998-1013, 2014	946	2014
Drug development of MET inhibitors: targeting oncogene addiction and expedience PM Comoglio, S Giordano, L Trusolino Nature reviews Drug discovery 7 (6), 504-516, 2008	852	2008
Scatter-factor and semaphorin receptors: cell signalling for invasive growth L Trusolino, PM Comoglio Nature Reviews Cancer 2 (4), 289-300, 2002	819	2002
A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer A Bertotti, G Migliardi, F Galimi, F Sassi, D Torti, C Isella, D Corà, ... Cancer discovery 1 (6), 508-523, 2011	709	2011
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	519	2013
A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth L Trusolino, A Bertotti, PM Comoglio Cell 107 (5), 643-654, 2001	510	2001
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016	490	2016
Stromal contribution to the colorectal cancer transcriptome C Isella, A Terrasi, SE Bellomo, C Petti, G Galatola, A Muratore, A Mellano, ... Nature genetics 47 (4), 312-319, 2015	411	2015
Interrogating open issues in cancer precision medicine with patient-derived xenografts AT Byrne, DG Alférez, F Amant, D Annibali, J Arribas, AV Biankin, A Bruna, ... Nature Reviews Cancer 17 (4), 254, 2017	339	2017
The Met tyrosine kinase receptor in development and cancer A Gentile, L Trusolino, PM Comoglio Cancer and Metastasis Reviews 27 (1), 85-94, 2008	318	2008
The genomic landscape of response to EGFR blockade in colorectal cancer A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou, B Lupo, M Sausen, ... Nature 526 (7572), 263-267, 2015	310	2015
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. G Tripodi, F Valtorta, L Torielli, E Chieregatti, S Salardi, L Trusolino, ... The Journal of clinical investigation 97 (12), 2815-2822, 1996	305	1996
Interactions between growth factor receptors and adhesion molecules: breaking the rules PM Comoglio, C Boccaccio, L Trusolino Current opinion in cell biology 15 (5), 565-571, 2003	279	2003
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ... Nature 568 (7753), 511-516, 2019	259	2019
Series Introduction: Invasive growth: from development to metastasis PM Comoglio, L Trusolino The Journal of clinical investigation 109 (7), 857-862, 2002	250	2002
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3 C Sun, S Hobor, A Bertotti, D Zecchin, S Huang, F Galimi, F Cottino, ... Cell reports 7 (1), 86-93, 2014	237	2014
Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils D Torti, L Trusolino EMBO molecular medicine 3 (11), 623-636, 2011	227	2011
HER2 activating mutations are targets for colorectal cancer treatment SM Kavuri, N Jain, F Galimi, F Cottino, SM Leto, G Migliardi, ... Cancer discovery 5 (8), 832-841, 2015	183	2015
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas G Migliardi, F Sassi, D Torti, F Galimi, ER Zanella, M Buscarino, D Ribero, ... Clinical Cancer Research 18 (9), 2515-2525, 2012	170	2012

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Upload PDF

Follow this author

Cited by

Co-authors